Potassium dehydroandrographolide succinate injection for treat- ment of infantile pneumonia: a systematic review and

Insights

Potassium dehydroandrographolide succinate injection (PDS) is effective and safe for treating infantile pneumonia, improving recovery times and symptoms. Higher quality studies are needed to confirm these findings for PDS efficacy.

Area of Science:

  • Pediatrics
  • Pharmacology
  • Evidence-Based Medicine

Background:

  • Infantile pneumonia is a common respiratory infection in children.
  • Potassium dehydroandrographolide succinate injection (PDS) is a potential therapeutic agent.
  • Systematic evaluation of PDS for infantile pneumonia is warranted.

Purpose of the Study:

  • To systematically evaluate the clinical efficacy and safety of PDS in treating infantile pneumonia.
  • To synthesize evidence from randomized controlled trials (RCTs).

Main Methods:

  • Searched multiple databases for RCTs of PDS in infantile pneumonia (1979-2013).
  • Assessed study quality using Cochrane risk of bias tool.
  • Conducted a meta-analysis using Review Manager 5.2.

Main Results:

  • Included 9 RCTs with 1056 participants; study quality was generally low.
  • PDS significantly improved total effective rate (RR=1.21) compared to conventional therapy.
  • PDS reduced temperature recovery time (MD=-1.43) and improved rale disappearance and cough relief (MD=-1.44).
  • Adverse drug reactions (rash, diarrhea) were reported but not serious.

Conclusions:

  • PDS demonstrates efficacy and relative safety for infantile pneumonia treatment.
  • The quality of included studies is a limitation.
  • Further high-quality RCTs are recommended to confirm PDS efficacy and safety.
Abstract

Related Concept Videos

Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
734
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
868
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
389
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.7K
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
1.1K
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
3.6K